New York, New York and Davis, California (PRWEB) June 15, 2015 -- The Joint Clinical Trials Office of Weill Cornell Medical College and NewYork-Presbyterian Hospital has signed an agreement with the California-based clinical technology and services company Mytrus to develop a pilot project introducing e-Consent technology into the oncology clinics at NewYork-Presbyterian/Weill Cornell Medical Center.
Electronic informed consent is an emerging technology supported by the U.S. Food and Drug Administration that has the potential to enhance the patient experience by making it easier for them to review and understand documents related to their care. Using a tablet computer, patients are guided through a presentation of their rights and responsibilities, as well as risks and benefits of the clinical trial they are considering. They can interact with the presentation by highlighting unfamiliar words to access definitions or further educational materials, for instance.
The program, built on Mytrus’ Enroll® software platform, may also streamline the process for doctors and researchers, and enable them to track consent status for future research. And it will allow the research team to notify subjects of any amendments or other information that may impact their ongoing participation in the study.
“This is an important step for Weill Cornell, NewYork-Presbyterian Hospital and, most importantly, for our patients,” said John P. Leonard, M.D., director of the Joint Clinical Trials Office and associate dean for clinical research at Weill Cornell. “At the heart of our mission as an academic medical center is to drive excellence in clinical care, and one of the key ways we strive to accomplish that is by empowering our patients to participate in the care they receive. We are pleased to collaborate with Mytrus and provide our patients with the tools and resources to control how their research data is used in clinical settings.”
“Weill Cornell Medical College and NewYork-Presbyterian are leaders among major academic institutions making the switch from paper to electronic informed consent,” said Mytrus co-founder and CEO Anthony Costello. “They share our vision of empowering patients to better understand the research process and expectations and to better track long term consent for ongoing studies.”
Learn more about the Joint Clinical Trials Office at Weill Cornell Medical College and NewYork-Presbyterian at jcto.weill.cornell.edu and Twitter @wcmcnypjcto.
Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances — including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian, where its faculty provides comprehensive patient care at NewYork-Presbyterian/Weill Cornell Medical Center. The Medical College is also affiliated with Houston Methodist. For more information, visit weill.cornell.edu.
NewYork-Presbyterian Hospital, based in New York City, is one of the nation’s largest and most comprehensive hospitals and a leading provider of inpatient, ambulatory and preventive care in all areas of medicine. With some 2,600 beds and more than 6,500 affiliated physicians and 20,000 employees, NewYork-Presbyterian had more than 2 million visits in 2013, including close to 15,000 infant deliveries and more than 310,000 emergency department visits. NewYork-Presbyterian comprises six campuses: NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian/Columbia University Medical Center, NewYork-Presbyterian/Morgan Stanley Children's Hospital, NewYork-Presbyterian/The Allen Hospital, NewYork-Presbyterian/Westchester Division and NewYork-Presbyterian/Lower Manhattan Hospital. The hospital is also closely affiliated with NewYork-Presbyterian/Hudson Valley Hospital and NewYork-Presbyterian/Lawrence Hospital. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area, according to U.S. News & World Report, and consistently named to the magazine’s Honor Roll of best hospitals in the nation. Affiliated with two world-renowned medical schools, Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, NewYork-Presbyterian is committed to excellence in patient care, research, education and community service. For more information, visit http://www.nyp.org.
Founded in 2009, Mytrus is a California-based clinical technology and services company which is revolutionizing traditional clinical trials with its simple, efficient, and patient-centered technologies. Creating interactive tools that improve patient comprehension and comfort, Mytrus streamlines the clinical trial process, dramatically improving patient recruitment timelines, increasing patient retention and reducing overall study costs for sponsors. At a time when bringing a drug to market can cost more than $1 billion, Mytrus provides solutions for academia, pharmaceutical, biotech and device makers eager to find more cost effective ways to conduct research.
Michael Tucker, Mytrus, Inc., http://www.mytrus.com, +1 (512) 535-5000, [email protected]
SOURCE Mytrus, Inc.